ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5108.26M
Enterprise Value 3100.96M
Trailing P/E N/A
Forward P/E 1-4.14
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)3.84
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (3Y Monthly) 0.93
52-Week Change 3-59.97%
S&P500 52-Week Change 36.42%
52 Week High 38.8500
52 Week Low 32.5100
50-Day Moving Average 33.4298
200-Day Moving Average 33.6898

Share Statistics

Avg Vol (3 month) 314.77k
Avg Vol (10 day) 39.22k
Shares Outstanding 532.05M
Float 28.14M
% Held by Insiders 10.00%
% Held by Institutions 19.35%
Shares Short (Jun 28, 2019) 474.07k
Short Ratio (Jun 28, 2019) 43.48
Short % of Float (Jun 28, 2019) 4N/A
Short % of Shares Outstanding (Jun 28, 2019) 40.23%
Shares Short (prior month May 31, 2019) 41.22k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in TWD.

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-48.40%
Return on Equity (ttm)-144.36%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)N/A
Diluted EPS (ttm)-1.1700
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)N/A
Total Cash Per Share (mrq)N/A
Total Debt (mrq)N/A
Total Debt/Equity (mrq)54.79
Current Ratio (mrq)3.80
Book Value Per Share (mrq)0.82

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A